Navigation Links
Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
Date:10/20/2009

BALTIMORE, Oct. 20 /PRNewswire/ -- Celsis International is pleased to announce that the United States Patent and Trademark Office today issued U.S. Patent No. 7,604,929 to Celsis In Vitro Technologies (Celsis IVT). This patent generally covers processes by which the company creates its unique LiverPool(TM) products for drug discovery research. The pooling process combines primary cells from multiple donors to create large lots with targeted activity levels. The resulting LiverPool product is flexible, customizable and repeatable, enabling scientists to run multiple studies on various compounds or NCEs anywhere in the world, and at any time, which speeds up decision making and reduces the time and cost of drug research.

"Our LiverPool product is a great example of Celsis IVT's pioneering work in developing ADME-Tox products that meet the research needs of our customers, while helping to take costs out of the drug discovery process," said Judy Madden, vice president of strategic development for Celsis. "We're proud that the US Patent Office has recognized our continued innovation and awarded us this patent."

Celsis IVT has been producing LiverPool products for more than five years and they have been incorporated into the standard research protocols of major pharmaceutical companies around the world. Research conducted with LiverPool has documented its efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies. Scientific posters and LiverPool product information are available online at www.celsis.com/liverpool.

About Celsis IVT

Celsis IVT is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development. Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization. Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research. Celsis IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's largest inventory) and other ADMET research tools are available worldwide. Visit www.celsis.com/ivt for more information.

About Celsis International

Chicago-based Celsis International is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers. Celsis' extensive client base includes leading pharmaceutical and consumer products companies, including all 25 of the top 25 pharmaceutical companies worldwide. Visit www.celsis.com.

SOURCE Celsis International


'/>"/>
SOURCE Celsis International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Chicago-Based Celsis International Goes Private
2. Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes
3. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
4. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
5. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
6. Celsis Receives Frost & Sullivan 2008 Best Practices Award
7. Peripheral Artery Disease (PAD) Patent Granted to Dimera
8. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
9. Delcath Systems Granted Third Orphan Drug Designation
10. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
11. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, ... sell research and genetic testing lab equipment from two different leading institutes. This highly ... Northeast regions of the United States. This 1-day online auction will take place ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017 Shareholder ... an investigation into whether the board members of CoLucid ... fiduciary duties in connection with the proposed sale of ... a biopharmaceutical company that develops small molecules for the ... 2017, CoLucid announced it had signed a definitive merger ...
(Date:1/18/2017)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF) ... and commercializes proprietary technologies and products for advanced ... that Cameron Prange , President of Kingsdale ... Board of Directors.  Mr. Prange,s resignation is related ... limited both his ability to act on behalf ...
(Date:1/17/2017)... ... January 17, 2017 , ... MS Technologies™ and Bayer ... GT Soybean Performance System will combine industry-leading genetics with a double herbicide-tolerant trait ... new Balance® Bean herbicide. The Balance™ GT Soybean Performance System will benefit soybean ...
Breaking Biology Technology:
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):